Robert MacLaren
Corporate Officer/Principal at University of Oxford
Profile
Robert MacLaren was the founder of NightstaRx Ltd.
(founded in 2014) and Nightstar Therapeutics Ltd.
(founded in 2014), where he held the title of Director and Independent Non-Executive Director, respectively.
Currently, he holds the position of Professor-Ophthalmology at the University of Oxford and Professor-Surgery at The Royal College of Surgeons of Edinburgh.
Dr. MacLaren obtained a doctorate degree from the University of Oxford and an undergraduate degree from The University of Edinburgh.
Robert MacLaren active positions
| Companies | Position | Start |
|---|---|---|
| University of Oxford | Corporate Officer/Principal | - |
| The Royal College of Surgeons of Edinburgh | Corporate Officer/Principal | - |
Former positions of Robert MacLaren
| Companies | Position | End |
|---|---|---|
| NIGHTSTAR THERAPEUTICS PLC | Founder | - |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Founder | - |
Training of Robert MacLaren
| University of Oxford | Doctorate Degree |
| The University of Edinburgh | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Robert MacLaren
